PRLD (Prelude Therapeutics) Additional Paid-In Capital: $841.32 Mil(As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

PRLD Prelude Therapeutics Inc PRLD
30 GF Score
Price $4.65
! 3 Warning Signs
View Full Analysis

What is Prelude Therapeutics Additional Paid-In Capital?

Prelude Therapeutics PRLD -7.98% 30 Additional Paid-In Capital is $841.32 Mil as of Jun. 2026. GuruFocus rates PRLD with a GF Score™ of 30/100. The stock has 3 warning signs investors should review.


Prelude Therapeutics's quarterly additional paid-in capital increased from Dec. 2025 ($751.68 Mil) to Mar. 2026 ($753.66 Mil) and increased from Mar. 2026 ($753.66 Mil) to Jun. 2026 ($841.32 Mil).

Prelude Therapeutics's annual additional paid-in capital increased from Dec. 2023 ($693.25 Mil) to Dec. 2024 ($714.98 Mil) and increased from Dec. 2024 ($714.98 Mil) to Dec. 2025 ($751.68 Mil).

Prelude Therapeutics Additional Paid-In Capital Related Terms

Prelude Therapeutics Additional Paid-In Capital Historical Data

* Premium members only.

The historical data trend for Prelude Therapeutics's Additional Paid-In Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Prelude Therapeutics Additional Paid-In Capital Chart

Prelude Therapeutics Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Additional Paid-In Capital
Get a 7-Day Free Trial 505.72 531.68 693.25 714.98 751.68

Prelude Therapeutics Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Additional Paid-In Capital Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 722.71 725.13 751.68 753.66 841.32
PRLD
30GF Score
Prelude Therapeutics Inc PRLD
Additional Paid-In Capital is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Prelude Therapeutics Additional Paid-In Capital Calculation

Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.

Additional Paid-In Capital is calculated as

Additional Paid-In Capital=(Issue Price-Par Value)* Shares Outstanding (Diluted Average)
What does a Additional Paid-In Capital of $841.32 Mil mean?
Prelude Therapeutics (PRLD) has a Additional Paid-In Capital of $841.32 Mil as of Jun. 2026. Additional paid-in capital is the capital a company raises in excess of par value. View historical data on Prelude Therapeutics and its competitors.
Is Prelude Therapeutics' Additional Paid-In Capital too high?
Prelude Therapeutics' current Additional Paid-In Capital is $841.32 Mil. Overall, Prelude Therapeutics has a GF Score™ of 30/100, reflecting its overall financial health beyond just this single metric.
How does Prelude Therapeutics' Additional Paid-In Capital compare to CMPX and ARCT?
Prelude Therapeutics' Additional Paid-In Capital of $841.32 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Additional Paid-In Capital for a Biotechnology company?
A good Additional Paid-In Capital depends on the Biotechnology industry context. However, Additional Paid-In Capital should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Additional Paid-In Capital mean?
A high Additional Paid-In Capital can signal that a stock is expensive relative to its fundamentals. Additional paid-in capital is the capital a company raises in excess of par value. View historical data on Prelude Therapeutics and its competitors. Prelude Therapeutics's current Additional Paid-In Capital is $841.32 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Prelude Therapeutics stock overvalued right now?
Prelude Therapeutics (PRLD) has a current Additional Paid-In Capital of $841.32 Mil. The current Additional Paid-In Capital is $841.32 Mil. Prelude Therapeutics' overall GF Score™ is 30/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Additional Paid-In Capital calculated?
Additional Paid-In Capital is calculated from a company's financial statements. For Prelude Therapeutics (PRLD), the current Additional Paid-In Capital is $841.32 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Prelude Therapeutics Business Description

Address 175 Innovation Boulevard, Wilmington, DE, USA, 19805
Prelude Therapeutics Incorp is a precision oncology company developing medicines in areas of high unmet need for cancer patients. Its pipeline features selective KAT6A degraders and mutant selective JAK2V617F JH2 inhibitors, new approaches to clinically validated targets with transformative potential for patients. The company is also leveraging its expertise in targeted protein degradation to discover and develop next-generation degrader antibody conjugates (DACs) with novel payloads.
30GF Score

Get the complete analysis for PRLD

Additional Paid-In Capital is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$4.65
Price